

Durham Research Online

Deposited in DRO:

01 February 2017

Version of attached file:

Accepted Version

Peer-review status of attached file:

Peer-reviewed

Citation for published item:

Webster, Alexandra M. and Cobb, Steven L. (2017) 'Synthesis of biaryl-linked cyclic peptoids.', *Tetrahedron letters*, 58 (10). pp. 1010-1014.

Further information on publisher's website:

<https://doi.org/10.1016/j.tetlet.2017.01.097>

Publisher's copyright statement:

This article is available under the terms of the Creative Commons Attribution License (CC BY). You may copy and distribute the article, create extracts, abstracts and new works from the article, alter and revise the article, text or data mine the article and otherwise reuse the article commercially (including reuse and/or resale of the article) without permission from Elsevier. You must give appropriate credit to the original work, together with a link to the formal publication through the relevant DOI and a link to the Creative Commons user license above. You must indicate if any changes are made but not in any way that suggests the licensor endorses you or your use of the work.

Additional information:

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.

Accepted Manuscript

Synthesis of Biaryl-Linked Cyclic Peptoids

Alexandra M. Webster, Steven L. Cobb

PII: S0040-4039(17)30140-5
DOI: <http://dx.doi.org/10.1016/j.tetlet.2017.01.097>
Reference: TETL 48600

To appear in: *Tetrahedron Letters*

Received Date: 25 November 2016
Revised Date: 20 January 2017
Accepted Date: 26 January 2017



Please cite this article as: Webster, A.M., Cobb, S.L., Synthesis of Biaryl-Linked Cyclic Peptoids, *Tetrahedron Letters* (2017), doi: <http://dx.doi.org/10.1016/j.tetlet.2017.01.097>


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical Abstract

Synthesis of Biaryl-Linked Cyclic Peptoids

Alexandra M. Webster and Steven L. Cobb

Leave this area blank for abstract info.





Tetrahedron Letters
journal homepage: www.elsevier.com

Synthesis of Biaryl-Linked Cyclic Peptoids

Alexandra M. Webster^a and Steven L. Cobb^{a, *}

^aDepartment of Chemistry, Durham University, South Road, Durham, DH1 3LE, U.K.

ARTICLE INFO

Article history:

Received
Received in revised form
Accepted
Available online

Keywords:

peptoid
peptidomimetic
cyclic
Suzuki cross-coupling
biaryl

ABSTRACT

Peptoids, a class of peptidomimetic, have gained considerable attention as potential therapeutic agents due to properties such as biocompatibility and resistance to enzymatic degradation. In linear peptoids, conformational heterogeneity can arise due to *cis/trans* isomerization around the backbone tertiary amide bond which has led to an increasing interest in cyclic peptoids. Biaryl linkages appear as a common structural motif in many synthetic and naturally occurring cyclic peptides but they are yet to be utilized in the formation of cyclic peptoids. Herein, we describe the application of a solid-phase Suzuki cross-coupling strategy as a means to prepare a series of biaryl-linked cyclic peptoids. The methodology presented allows access to a range of novel biaryl containing cyclic peptoids with varying ring sizes.

2009 Elsevier Ltd. All rights reserved.

* Corresponding author. E-mail: s.l.cobb@durham.ac.uk (S.L Cobb)

Introduction

Peptoids (*N*-substituted glycines) belong to a class of synthetic molecules known as peptidomimetics, so named because of their similarity in structure to peptides (Fig. 1).^{1,2} Like peptides, peptoids are oligomeric in nature and they contain side-chains (R) which may comprise of a wide variety of functional groups. However, a peptoid's backbone is devolved entirely of tertiary amide bonds, and, this in turn gives them a range of different physical and biological properties to peptides.





Figure 1. Comparison of α -peptide and α -peptoid structures.

For example, peptoids are highly resistant to enzymatic degradation,³ making them desirable molecules for a range of biological applications including imaging probes,⁴ antimicrobials,⁵⁻⁷ antifungal⁸ and anticancer⁴ agents. In addition the lack of an amide NH within the backbone means that there is no capacity to use hydrogen bonding to stabilize the formation of discretely folded secondary structures. Peptoids thus display an increased conformational flexibility over peptides, and controlling the *cis-trans* isomer profile in the backbone can be challenging.⁹

This lack of a defined (or inherent) secondary structure in many peptoids presents an obstacle to their use as therapeutics due to the fact that good selectivity and binding affinity for a particular target often requires conformational rigidity.^{10,11} Cyclisation offers a well-established process to modulate conformational flexibility in peptides^{12, 13} and leading on from this various strategies have been developed to cyclise peptoids. These include solution phase head-to-tail condensation,¹⁴⁻¹⁷ side-chain "stapling" *via* Grubbs metathesis,¹⁸ halide substitution¹⁹ and copper-catalysed azide-alkyne cycloaddition (CuAAC).^{20, 21}

Within our laboratory we are interested in the development of new building blocks and approaches that can be used to access biaryl containing cyclic peptides.²² The biaryl motif is commonly found in a range of important naturally occurring peptides including Vancomycin and the Biphenomycins as well as synthetic Arylomycin A2.^{23, 24} The biaryl motif has also received considerable attention from the pharmaceutical industry and it appears commonly in many compounds that have activity as anti-fungal, anti-tumour, anti-hypertensive and anti-inflammatory agents.²⁵⁻²⁷ Given the attention directed towards biaryl motifs in peptide chemistry²⁸⁻³⁰ it is surprising that within the field of peptoid chemistry little work in this area has been reported.³¹ Elegant recent work by Nam and Seo demonstrated the application of a Suzuki-Miyaura cross-coupling strategy as a means to access linear peptoids containing novel biaryl monomers.³² The aforementioned work utilized an intermolecular Suzuki cross-coupling process (i.e. arylboronic acid added to an aryl-halide monomer on resin) and to the best of our knowledge the corresponding intramolecular reaction has not yet been exploited to access biaryl containing cyclic peptoids.

Herein, we report the preparation of a series of novel cyclic peptoids scaffolds that contain a biaryl linkage. Preparation of a range of ring sizes are demonstrated and ring closure has been achieved using an on-resin Suzuki cross-coupling strategy.




Results and Discussion


In order to access cyclic peptoids *via* a Suzuki cross-coupling approach the linear parent peptoid has to contain both an aromatic halide (e.g. bromide or iodide) and an aromatic boronic acid. The established sub-monomer peptoid synthesis strategy¹ was used to build up the linear peptoid on Rink Amide resin and incorporation of the required aromatic halide was achieved using commercially available, 3-iodobenzylamine (**1**) (Scheme 1).

Incorporation of the aromatic boronic acid component was achieved using commercially available 3-carboxyphenyl boronic acid MIDA ester (**2**) with diisopropylcarbodiimide (DIC, Scheme 1). The boronic acid (**2**) is protected with *N*-methyliminodiacetic acid (MIDA), deprotection of which is afforded by treatment in aqueous base at room temperature.³³ MIDA boronates have been shown to be highly air stable, resistant to a wide variety of synthetic conditions³⁴ and previous work within the group in which MIDA boronate-containing peptides were synthesised, confirms their stability towards amide bond coupling conditions.²²


The sequence of the first linear peptoid (**3**) chosen for cyclisation was designed to allow a relatively unstrained ring system to be accessed. We also incorporated Boc-protected amino butane monomers (Boc-*N*Lys) to aid solubility upon peptoid cleavage from the resin. We wanted to carry out the cyclisation/ Suzuki cross-coupling whilst the parent linear peptoid (**3**) was still on resin. The advantages of carrying out the cross-coupling reaction whilst on resin are two-fold: firstly, there is no need to cleave and purify the linear parent peptoid which is not only time consuming, but can often result in loss of overall yield. Secondly, after the Suzuki cross-coupling reaction has been carried out, any unreacted reagents (e.g. metals) and side-products can simply be removed by washing the resin, making purification of the final cyclic product easier. For the Suzuki cross-coupling we selected reaction conditions based on the previously reported work of Nam and Seo³² and our own experiences of working with MIDA-protected amino acids.²²



Scheme 1. Incorporation of 3-iodobenzylamine (**1**) and 3-carboxyphenylboronic acid MIDA ester (**2**) into a linear peptide (**3**).



Scheme 2. Solid phase cyclisation of parent linear peptide (**3**) into resin bound cyclic peptide (**4**) *via* Suzuki cross-coupling, followed by cleavage from the resin to give the free cyclic peptide (**5**).



















Scheme 3. Solid phase cyclisation of parent linear peptide (**7**) into resin bound cyclic peptide (**8**) *via* Suzuki cross-coupling, followed by cleavage from the resin to give the free cyclic peptide (**9**).

The cyclisation of the on resin linear peptide (**3**) was therefore attempted using tetrakis palladium (5 mol%), Buchwald's ligand, and K_2CO_3 in DMF at 80 °C for 8 h. It should be noted that as the reaction procedure used K_2CO_3 in excess we did not carry out a separate deprotection step for the MIDA-protected boronate ester prior to carrying out the on resin Suzuki cross-coupling reaction.

Following cleavage from the resin (TFA/DCM) cyclic peptide **5** was isolated in a 15% yield as a water soluble white solid after reverse phase semi-preparative HPLC purification. While not isolated it is worth noting that the un-cyclised peptide by-product (**6**) was observed in the LCMS of the crude reaction mixture.

Table 1. Library of linear and cyclic peptides

Linear peptide	Cyclic peptide ^a	Yield ^b (%)
 <p>3</p>	 <p>5</p>	15
 <p>7</p>	 <p>9</p>	9
 <p>11</p>	 <p>17</p>	23
 <p>12</p>	 <p>18</p>	22
 <p>13</p>	 <p>19</p>	14
 <p>14</p>	 <p>20</p>	13
 <p>15</p>	 <p>21</p>	3
 <p>16</p>	 <p>22</p>	17

^aCyclic peptides synthesized from linear parent peptides under the conditions shown in Schemes 3 and 4^bIsolated yields are calculated assuming that parent linear peptides were synthesized with full conversion

Next, we wanted to probe the effects of flexibility and overall sequence length of the linear peptoid chain on the cyclisation reaction. To test this, we replaced one of the *N*Lys residues with a glycine monomer (increase in flexibility) and the synthesis of the linear parent peptoid (**7**) was completed by addition of 3-carboxyphenylboronic acid to the *N*-terminus as shown in Scheme 3. Suzuki cross-coupling, cleavage from the resin and subsequent HPLC purification gave the biaryl-containing cyclic peptoid **9** in 9% yield (Scheme 3). It should be noted that ESI LCMS analysis of the crude reaction mixture prior to HPLC purification again showed that the corresponding dehalogenation/deboronated product (**10**) was present.

Having successfully isolated biaryl-containing cyclic peptoids **5** and **9**, we then proceeded to synthesise a small library of linear peptoids containing both an aromatic iodide and regio-isomeric MIDA-protected boronates (Table 1, **11-16**). We carried out the Suzuki cross-couplings on each linear peptoid using the same reaction conditions in order to enable a simple comparison regarding the ease of ring formation (Table 1). Biaryl-containing cyclic peptoids were isolated from all of the linear sequences investigated, however, the isolated yields varied. Perhaps predictably, the longer sequences (**13-16**) appeared to be more difficult to cyclise, presumably due to a larger entropic penalty associated with constraining more flexible chains. With the exception of cyclic peptoids **9** and **20**, in each case, the yield of the cyclic peptoid recovered was lower as the sequence increased in length. For the shorter linear peptoids containing the 3-MIDA boronate building block (i.e. compare **3** and **7**) incorporation of a less hindered glycine monomer into the sequence (**7**) reduced the yield of the cyclic peptoid obtained (i.e. compare **5** and **9**). This may indicate that the *N*Lys monomer confers some level of secondary structure in the linear peptoid (**3**) that makes the cross-coupling cyclisation reaction more favorable, whereas the extra flexibility conferred by the glycine monomer in **7** results in a greater entropic penalty having to be paid. Interestingly, the opposite is seen for the longer peptoids (i.e. **21** and **22**) with the glycine-containing linear peptoid (**16**) cyclising more readily than the *N*Lys-containing counterpart (**15**).

For the shorter linear peptoids containing the 4-MIDA boronate building block (**11** and **12**), the presence of the *N*Lys side-chain versus the glycine monomer appeared to make little difference to the efficiency of cyclisation, however, both resulting cyclic peptoids (**17** and **18**) were isolated in higher yields than the cyclic peptoids (**5** and **9**) formed from the corresponding shorter 3-MIDA boronate containing linear peptoids (**3** and **7**). This perhaps suggests that the formation of 3,4-biaryl-linked cyclic peptoids (**17** and **18**) is favored over the formation of the corresponding 3,3-biaryl-linked cyclic peptoids (**5** and **9**). The same trend is also seen as peptoid sequence length is increased, i.e. 3,4-biaryl-linked cyclic peptoid **22** was isolated in a higher yield than the corresponding 3,3-biaryl-linked cyclic peptoid **20**. However, given that the isolated yields in all of the aforementioned cases were not significantly different, it is difficult to draw any definitive conclusions from the data obtained. To gain more accurate information would require the linear peptoids to be cleaved and purified prior to Suzuki cross-coupling, but as discussed earlier the on-resin cyclisation confers many advantages in the overall synthetic strategy.

Conclusions

The primary aim of this study was to prepare a series of linear peptoids with suitable functionality that could be cyclised *via* an on-resin Suzuki cross-coupling in order to obtain novel biaryl-linked cyclic peptoids. This was achieved and a small library of cyclic peptoids with varying ring sizes and differing biaryl connectivity (i.e. 3,3- and 3,4-biaryl linkages) were prepared and isolated. With the initial concept established, optimization of the on-resin cyclisation reaction is now ongoing and the formation of bi-cyclic biaryl-containing peptoids *via* application of novel MIDA-protected monomers is being explored. The biaryl-linked cyclic peptoids prepared are also undergoing biological evaluation and the results will be reported in due course.

Acknowledgments

We thank the Engineering and Physical Sciences Research Council (EPSRC) for funding (Chemistry Department DTG, AMW).

References

- Zuckermann, R. N.; Kerr, J. M.; Kent, S. B. H.; Moos, W. H. *J. Am. Chem. Soc.* **1992**, *114*, 10646.
- Vagner, J.; Qu, H.; Hruby, V. J. *Curr. Opin. Chem. Biol.* **2008**, *12*, 292.
- Miller, S. M.; Simon, R. J.; Ng, S.; Zuckermann, R. N.; Kerr, J. M.; Moos, W. H. *Bioorg. Med. Chem. Lett.* **1994**, *4*, 2657.
- Huang, W.; Seo, J.; Willingham, S. B.; Czyzewski, A. M.; Gonzalgo, M. L.; Weissman, I. L.; Barron, A. E. *PLoS One* **2014**, *9*, e90397.
- Chongsiriwatana, N. P.; Patch, J. A.; Czyzewski, A. M.; Dohm, M. T.; Ivankin, A.; Gidalevitz, D.; Zuckermann, R. N.; Barron, A. E. *Proc. Natl. Acad. Sci.* **2008**, *105*, 2794.
- Bolt, H. L.; Eggmann, G. A.; Denny, P. W.; Cobb, S. L. *MedChemComm* **2016**, *7*, 799.
- Luo, Y.; Bolt, H. L.; Eggmann, G. A.; Mc Auley, D. F.; Mc Mullan, R.; Curran, T.; Zhou, M.; Jahoda, C. A. B.; Cobb, S. L.; Lundy, F. T. *ChemBioChem* **2016**, n/a.
- Galetti, M. D.; Cirigliano, A. M.; Cabrera, G. M.; Ramírez, J. A. *Mol. Diversity* **2011**, *16*, 113.
- Roy, O.; Caumes, C.; Esvan, Y.; Didierjean, C.; Faure, S.; Taillefumier, C. *Org. Lett.* **2013**, *15*, 2246.
- Ivankin, A.; Antipova, A.; Radzishewsky, I.; Mor, A.; Caputo, G. A.; DeGrado, W. F.; Gidalevitz, D. *Biophys. J.* **2010**, *98*, 85a.
- Strebhardt, K. *Nat. Rev. Drug Discov.* **2010**, *9*, 643.]
- Jefferson, E. A.; Seth, P. P.; Robinson, D. E.; Winter, D. K.; Miyaji, A.; Risen, L. M.; Osgood, S. A.; Bertrand, M.; Swayze, E. E. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 5257.
- Thorsthalm, L.; Craik, D. J. *Drug Discovery Today: Technol.* **2012**, *9*, e13.
- Shin, S. B. Y.; Yoo, B.; Todaro, L. J.; Kirshenbaum, K. *J. Am. Chem. Soc.* **2007**, *129*, 3218.
- Yoo, B.; Shin, S. B. Y.; Huang, M. L.; Kirshenbaum, K. *Chem. Eur. J.* **2010**, *16*, 5528.
- Huang, M. L.; Benson, M. A.; Shin, S. B. Y.; Torres, V. J.; Kirshenbaum, K. *Eur. J. Org. Chem.* **2013**, *2013*, 3560.
- Vollrath, S. B. L.; Hu, C.; Brase, S.; Kirshenbaum, K. *Chem. Commun.* **2013**, *49*, 2317.
- Khan, S. N.; Kim, A.; Grubbs, R. H.; Kwon, Y.-U. *Org. Lett.* **2011**, *13*, 1582.
- a) Park, S.; Kwon, Y.-U. *ACS Comb. Sci.* **2015**, *17*, 196; b) Kaniraj, P. J.; Maayan, G. *Org. Lett.*, **2015**, *17*, 2110.
- Holub, J. M.; Jang, H.; Kirshenbaum, K. *Org. Lett.* **2007**, *9*, 3275.
- Jagasia, R.; Holub, J. M.; Bollinger, M.; Kirshenbaum, K.; Finn, M. G. *J. Org. Chem.* **2009**, *74*, 2964.
- Colgin, N.; Flinn, T.; Cobb, S. L. *Org. Biomol. Chem.* **2011**, *9*, 1864.
- Feliu, L.; Planas, M. *Int. J. Pept. Res. Ther.* **2005**, *11*, 53.
- Roberts, T. C.; Smith, P. A.; Cirz, R. T.; Romesberg, F. E. *J. Am. Chem. Soc.* **2007**, *129*, 15830.
- Hyung, K. E.; Lee, M. J.; Lee, Y.-J.; Lee, D. I.; Min, H. Y.; Park, S.-Y.; Min, K. H.; Hwang, K. W. *Int. Immunopharmacol.* **2016**, *32*, 125.
- Horton, D. A.; Bourne, G. T.; Smythe, M. L. *Chem. Rev.* **2003**, *103*, 893.

27. Kohler, C.; Tolman, E.; Wooding, W.; Ellenbogen, L. *Arzneimittel-Forschung* **1980**, *30*, 702.
28. Mendive-Tapia, L.; Preciado, S.; García, J.; Ramón, R.; Kielland, N.; Albericio, F.; Lavilla, R. *Nat. Commun.* **2015**, *6*, 7160.
29. Yoburn, J. C.; Deb, S.; Manfield, I. W.; Stockley, P. G.; Vranken, D. L. V. *Bioorg. Med. Chem.* **2003**, *11*, 811.
30. Meyer, F.-M.; Collins, J. C.; Borin, B.; Bradow, J.; Liras, S.; Limberakis, C.; Mathiowetz, A. M.; Philippe, L.; Price, D.; Song, K.; James, K. *J. Org. Chem.* **2012**, *77*, 3099.
31. a) Chung, S.-H.; Lin, T.-J.; Hu, Q.-Y.; Tsai, C.-H.; Pan, P.-S. *Molecules* **2013**, *18*, 12346; b) Goff, D. A.; Zuckermann, R. N. *J. Org. Chem.* **1995**, *60*, 5744.
32. Nam, H. Y.; Seo, J. *Pept. Sci.* **2016**, *106*, 82.
33. Gillis, E. P.; Burke, M. D. *J. Am. Chem. Soc.* **2008**, *130*, 14084.
34. Knapp, D. M.; Gillis, E. P.; Burke, M. D. *J. Am. Chem. Soc.* **2009**, *131*, 6961.

Research Highlights

- Synthesis of MIDA boronate-containing linear peptoids
- On resin Suzuki cross-coupling of linear peptoids
- Preparation of novel biaryl-linked cyclic peptoids